Table 1. Associations between patient characteristics and ICL Score.
| Characteristics | Patients | IFN-inducible CXCR3 ligands (ICL) Score | ||||
|---|---|---|---|---|---|---|
| Total (%) | I (n = 77) | II (n = 64) | III (n = 71) | IV (n = 51) | P | |
| Age (years)† | 0.405 | |||||
| Mean | 56.7 | 56.0 | 58.7 | 55.5 | 57.1 | |
| Median | 56 | 54 | 57.5 | 54 | 59 | |
| IQR | 48–67 | 47–66 | 51–67 | 46–65 | 46–68 | |
| Gender | 0.441 | |||||
| Male | 184 (70.0) | 52 | 50 | 48 | 34 | |
| Female | 79 (30.0) | 25 | 14 | 23 | 17 | |
| Tumor size (cm) † | 0.122 | |||||
| Mean | 4.6 | 4.2 | 4.4 | 4.8 | 5.4 | |
| Median | 4 | 3.5 | 4 | 4 | 5 | |
| IQR | 3–6 | 2.7–5.5 | 3–5.3 | 3–6 | 3–7 | |
| pT stage | 0.223 | |||||
| pT1 | 169 (17.5) | 56 | 41 | 45 | 27 | |
| pT2 | 33 (12.5) | 10 | 7 | 10 | 6 | |
| pT3 | 61 (23.2) | 11 | 16 | 16 | 18 | |
| Fuhrman grade | 0.004* | |||||
| 1 | 46 (17.5) | 18 | 16 | 10 | 2 | |
| 2 | 116 (44.1) | 35 | 33 | 28 | 20 | |
| 3 | 67 (25.5) | 18 | 12 | 20 | 17 | |
| 4 | 34 (12.9) | 6 | 3 | 13 | 12 | |
| Necrosis | 0.027* | |||||
| Absent | 202 (76.8) | 62 | 51 | 58 | 31 | |
| Present | 61 (23.2) | 15 | 13 | 14 | 20 | |
| ECOG-PS | 0.852 | |||||
| 0 | 226 (85.9) | 65 | 57 | 60 | 44 | |
| ≥ 1 | 37 (14.1) | 12 | 7 | 11 | 7 | |
| MVI | 0.602 | |||||
| Absent | 203 (77.2) | 62 | 46 | 54 | 41 | |
| Present | 60 (22.8) | 15 | 18 | 17 | 10 | |
| SSIGN | 0.001* | |||||
| 0–3 | 188 (71.5) | 64 | 52 | 46 | 26 | |
| 4–7 | 68 (25.8) | 13 | 12 | 22 | 21 | |
| ≥ 8 | 7 (2.7) | 0 | 0 | 3 | 4 | |
IQR, Interquartile range; MVI, Microvascular invasion; ECOG-PS, Eastern Cooperative Oncology Group performance status; SSIGN, the Mayo Clinic stage, size, grade, and necrosis score.
†
The results were calculated by Kruskal-Wallis test.
*
P < 0.05 is considered statistically significant.